Biogen Earnings Miss Estimates, But Outlook In-Line
Biogen Idec missed Wall Street's first-quarter estimates Tuesday, but blamed one-time events and guided the rest of the year within analysts' expected range. Biogen (BIIB) said sales rose 7% over the year-ago quarter to $1.3 billion, a hair under what analysts expected. But profit of $1.40 a share was down from last year and 8 cents below estimates. Biogen guided 2012 financials in-line with estimates, which call for 6.4% sales growth to $5.37
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here